Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer

We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. Patients with advanced-stage NSCLC treated wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ramalingam, Suresh S., Owonikoko, Taofeek K., Behera, Madhusmita, Subramanian, Janakiraman, Saba, Nabil F., Kono, Scott A., Gal, Anthony A., Sica, Gabriel, Harvey, R. Donald, Chen, Zhengjia, Klass, Carmen M., Shin, Dong M., Fu, Haian, Sun, Shi-yong R., Govindan, Ramaswamy, Khuri, Fadlo R.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126230/
https://ncbi.nlm.nih.gov/pubmed/23407561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318282709c
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars